公开(公告)号：EP1499291B1

公开(公告)日：2009-01-07

申请号：EP03728526.9

申请日：2003-04-25

申请人： ALZA Corporation

发明人： AYER, Atul ,  SHIVANAND, Padmaja ,  MODI, Nishit, B. ,  SEROFF, Sonya ,  DESJARDIN, Michael, A. ,  FINK, Tracy, A. ,  HEARNEY, Linda, M. ,  JOHNSON, Deborah, J. ,  ALLPHIN, Clark, P.

IPC分类号： A61K9/00 ,  A61K9/22 ,  A61P25/04

CPC分类号： A61K9/0004 ,  A61K31/485

摘要： Dosage forms and methods for the controlled release of oxycodone over a prolonged period of time are described. The sustained release dosage forms provide therapeutically effective average steady-state plasma oxycodone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma oxycodone concentration occurrence in each 24 hour period that occurs at a later time after administration and exhibits a lesser magnitude than the peak plasma oxycodone concentration that occurs following administration of oxycodone in an immediate-release dosage form and other prior art extended release dosage forms.

公开(公告)号：EP1802286A1

公开(公告)日：2007-07-04

申请号：EP05779051.1

申请日：2005-08-02

申请人： ALZA CORPORATION

发明人： CASADEVALL, Gemma ,  SUBRAMANIAN, Ramkumar ,  BARCLAY, Brian ,  ALLPHIN, Clark ,  SHIVANAND, Padmaja ,  YAM, Noymi, V.

IPC分类号： A61K9/50 ,  A61K9/20

CPC分类号： A61K9/1635 ,  A61K9/1652 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/209 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5084 ,  A61K31/519

摘要： Disclosed are dosage forms and methods for sustained release of a drug including : a delay layer comprising a polymeric matrix, and microencapsulated drug, wherein the delay layer is substantially free of non-microencapsulated drug; and a second layer including a polymeric matrix, and non-microencapsulated drug matrix; wherein the second layer is located adjacent to the delay layer.

公开(公告)号：EP1528913A1

公开(公告)日：2005-05-11

申请号：EP03762340.2

申请日：2003-06-28

申请人： Alza Corporation

发明人： LI, Shaoling ,  DONG, Liang-Chang ,  SHIVANAND, Padmaja ,  WONG, Patrick, S.L.

IPC分类号： A61K9/00 ,  A61K9/28 ,  A61K9/10 ,  A61K9/48 ,  A61K31/085

CPC分类号： A61K9/0004 ,  A61K31/085

摘要： The present invention includes an expandable osmotic layer and a coating suspension for providing an expandable osmotic layer, both of which are useful for the manufacture of controlled release dosage forms. The expandable osmotic layer of the present invention may be produced using the coating suspension of the present invention. Advantageously, the coating suspension of the present invention can be used to coat expandable osmotic layers under both wet and dry process conditions without sacrificing the quality of the expandable osmotic layers produced, and therefore provides a relatively robust coating suspension that facilitates commercial production of controlled release dosage forms including a coated expandable osmotic layer.

公开(公告)号：EP0957899B1

公开(公告)日：2003-03-19

申请号：EP97936421.3

申请日：1997-08-08

申请人： ALZA Corporation

发明人： SHIVANAND, Padmaja ,  AYER, Atul, D. ,  WRIGHT, Jeri, D. ,  LAM, Andrew ,  HAMEL, Lawrence, G.

IPC分类号： A61K9/00

CPC分类号： A61K9/0004

摘要： A bilayer and trilayer tablet and a dosage form are disclosed for administering a controlled and increasing dose of drug over time. A method is disclosed also for administering an increasing dose of drug over time.

公开(公告)号：EP1216058A2

公开(公告)日：2002-06-26

申请号：EP00973370.0

申请日：2000-09-19

申请人： Alza Corporation

发明人： SHIVANAND, Padmaja ,  AYER, Atul, D. ,  MARKS, Susan, M.

IPC分类号： A61K47/30 ,  A61K9/16

CPC分类号： A61K9/0004 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/1658 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2063

摘要： The present invention is directed to maintaining a therapeutic agent comprising a drug in its preferred polymorphic form for providing an indicated therapy. The therapeutic agent is maintained in the polymorphic form by blending a polymer with the therapeutic agent which lessens the conversion of the therapeutic agent from the desired form to a different, undesired form.

公开(公告)号：EP1677798A2

公开(公告)日：2006-07-12

申请号：EP04817492.4

申请日：2004-10-28

申请人： ALZA CORPORATION

发明人： HWANG, Stephen ,  MODI, Nishit, B. ,  SHIVANAND, Padmaja

IPC分类号： A61K31/485

CPC分类号： A61K31/485 ,  A61K9/0004 ,  A61K2300/00

摘要： Oxycodone formulations are provided which produce substantially flat in vivo steady state plasma profiles. Tolerance levels associated with such profiles and tolerance levels associated with biphasic profiles are shown not to be statistically different. The substantially flat in vivo steady state plasma profiles are produced by dosage forms having substantially zero order in vitro release profiles. Such release profiles produce low single dose in vivo Cmax levels which can reduce the probability of adverse side effects.

公开(公告)号：EP1499291A1

公开(公告)日：2005-01-26

申请号：EP03728526.9

申请日：2003-04-25

申请人： Alza Corporation

发明人： AYER, Atul ,  SHIVANAND, Padmaja ,  MODI, Nishit, B. ,  SEROFF, Sonya ,  DESJARDIN, Michael, A. ,  FINK, Tracy, A. ,  HEARNEY, Linda, M. ,  JOHNSON, Deborah, J. ,  ALLPHIN, Clark, P. ,  RASHID, Ayesha

IPC分类号： A61K9/00 ,  A61K9/22 ,  A61P25/04

CPC分类号： A61K9/0004 ,  A61K31/485

摘要： Dosage forms and methods for the controlled release of oxycodone over a prolonged period of time are described. The sustained release dosage forms provide therapeutically effective average steady-state plasma oxycodone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma oxycodone concentration occurrence in each 24 hour period that occurs at a later time after administration and exhibits a lesser magnitude than the peak plasma oxycodone concentration that occurs following administration of oxycodone in an immediate-release dosage form and other prior art extended release dosage forms.

公开(公告)号：EP1059917A1

公开(公告)日：2000-12-20

申请号：EP99909667.0

申请日：1999-02-26

申请人： ALZA CORPORATION

发明人： DAVAR, Nipun ,  AYER, Atul, D. ,  HWANG, Paul, M. ,  POLLOCK, Brenda, J. ,  SHIVANAND, Padmaja

IPC分类号： A61K9/24 ,  A61K9/20

CPC分类号： A61K31/41 ,  A61K9/0004 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/352 ,  A61K31/381 ,  A61K31/4045 ,  A61K31/47

摘要： A dosage form is disclosed for administering a leukatriene-receptor antagonist to a patient over time.

公开(公告)号：EP0946151A1

公开(公告)日：1999-10-06

申请号：EP97947642.0

申请日：1997-11-12

申请人： ALZA CORPORATION

发明人： HAMEL, Lawrence, G. ,  AYER, Atul, Devdatt ,  WRIGHT, Jeri, D. ,  LAM, Andrew ,  SHIVANAND, Padmaja

IPC分类号： A61K9 ,  A61K31 ,  A61K45

CPC分类号： A61K9/0004

摘要： A dosage form and a method are disclosed for delivering to a human patient a drug in an ascending amount over time.

公开(公告)号：EP1233761B1

公开(公告)日：2007-03-28

申请号：EP00980663.9

申请日：2000-11-21

申请人： ALZA CORPORATION

发明人： AYER, Atul, D. ,  SHIVANAND, Padmaja

IPC分类号： A61K9/24

CPC分类号： A61K9/0004

摘要： A dosage form is described having a drug core, an inner, fluid-permeable membrane surrounding the drug core, and an outer, semipermeable membrane having exit means formed or formable therein surrounding the inner membrane. The drug core forms a solution with imbibed fluid through the membranes and dissolves the inner membrane over time, thereby furthering the maintenance of controlled, sustained delivery of drug from the dosage form.